Study suggests greater CD8+ T-cell activity may increase HIV immunity.

Friday, December 15, 2023 NIH Research Identifies Opportunities to Improve Future HIV Vaccine Candidates Layout featuring colorized 3D prints of HIV virus particles (pink with teal surface proteins) and a background image that is a colorized transmission electron micrograph of HIV virus particles (pink) budding and replicating from an H9 T cell (purple). Micrograph captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Note: not to scale. Credit: NIAID A new study from the HIV-Specific Immunity Section of NIAID's Laboratory of Immunoregulation and colleagues found strong responses from immune cells called CD8+ T cells may play a key role in an effective HIV vaccine. These findings, published in Science, could guide development of future HIV vaccines and immunotherapy approaches. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107